Net Cash Provided by (Used in) Financing Activities of Altimmune, Inc. from 31 Dec 2010 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Altimmune, Inc. annual and quarterly Net Cash Provided by (Used in) Financing Activities in USD history and change rate from 31 Dec 2010 to 31 Dec 2025.
  • Altimmune, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending 31 Mar 2025 was $34,119,000.
  • Altimmune, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2025 was $206,842,000, a 1959% increase from 2024.
  • Altimmune, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2024 was $10,044,000, a 88% decline from 2023.
  • Altimmune, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $86,105,000, a 52% increase from 2022.
Source SEC data
View on sec.gov
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Change (%)
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Change (%)

Altimmune, Inc. Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $206,842,000 +$196,798,000 +1959% 01 Jan 2025 31 Dec 2025 10-K 06 Mar 2026 2025 FY
2024 $10,044,000 -$76,061,000 -88% 01 Jan 2024 31 Dec 2024 10-K 06 Mar 2026 2025 FY
2023 $86,105,000 +$29,324,000 +52% 01 Jan 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
2022 $56,781,000 -$8,317,000 -13% 01 Jan 2022 31 Dec 2022 10-K 27 Mar 2024 2023 FY
2021 $65,098,000 -$148,388,712 -70% 01 Jan 2021 31 Dec 2021 10-K 28 Feb 2023 2022 FY
2020 $213,486,712 +$200,954,606 +1604% 01 Jan 2020 31 Dec 2020 10-K 15 Mar 2022 2021 FY
2019 $12,532,106 -$19,957,799 -61% 01 Jan 2019 31 Dec 2019 10-K 25 Feb 2021 2020 FY
2018 $32,489,905 +$16,648,531 +105% 01 Jan 2018 31 Dec 2018 10-K 27 Mar 2020 2019 FY
2017 $15,841,374 01 Jan 2017 31 Dec 2017 10-K 01 Apr 2019 2018 FY
2012 $3,720,071 -$2,061,257 -36% 01 Jan 2012 31 Dec 2012 10-K 14 Mar 2013 2012 FY
2011 $5,781,328 -$15,679,124 -73% 01 Jan 2011 31 Dec 2011 10-K 14 Mar 2013 2012 FY
2010 $21,460,452 01 Jan 2010 31 Dec 2010 10-K 14 Mar 2013 2012 FY

Altimmune, Inc. Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $34,119,000 +$34,380,000 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q1 2024 $261,000 +$41,000 +14% 01 Jan 2024 31 Mar 2024 10-Q 13 May 2025 2025 Q1
Q1 2023 $302,000 -$3,483,000 -109% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q1 2022 $3,181,000 -$31,238,000 -91% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q1 2021 $34,419,000 +$34,322,287 +35489% 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022 2022 Q1
Q1 2020 $96,713 -$12,602,395 -99% 01 Jan 2020 31 Mar 2020 10-Q 17 May 2021 2021 Q1
Q1 2019 $12,699,108 +$12,680,620 01 Jan 2019 31 Mar 2019 10-Q 13 May 2020 2020 Q1
Q1 2018 $18,488* 01 Jan 2018 31 Mar 2018 10-Q 14 May 2019 2019 Q1
Q1 2015 $165,667 -$1,543,112 -112% 01 Jan 2015 31 Mar 2015 10-Q 07 May 2015 2015 Q1
Q1 2014 $1,377,445 +$1,437,806 01 Jan 2014 31 Mar 2014 10-Q 07 May 2015 2015 Q1
Q1 2013 $60,361 -$3,264,975 -102% 01 Jan 2013 31 Mar 2013 10-Q 08 May 2014 2014 Q1
Q1 2012 $3,204,614 +$3,191,854 01 Jan 2012 31 Mar 2012 10-Q 08 May 2013 2013 Q1
Q1 2011 $12,760* 01 Jan 2011 31 Mar 2011 10-Q 10 May 2012 2012 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.